Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping

Overview of attention for article published in Trends in Pharmacological Sciences, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 10 X users

patent: 4 patents

Readers on

mendeley: 122 Mendeley

So far, Altmetric has seen 12 X posts from 10 X users, with an upper bound of 192,660 followers.

As Novartis gets approval for a SMA therapy and sets the price for the drug at $2.1 million, lets look at one of the other potential therapies for the disease, on the horizon #raredisease #antisenseoligonucleotides https://t.co/Jk69l3PmL4

RT @CellPressNews: We're celebrating the reviews that inspired us in 2018. Read the full collection, including the pick from Trends in Phar…

We're celebrating the reviews that inspired us in 2018. Read the full collection, including the pick from Trends in Pharmacological Sciences: Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping @TrendsinPharma @MurdochUni http…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.